Persist AI has successfully raised $12 million to advance their innovative AI-driven mRNA platform development for drug discovery. This funding will support the integration of robotics in drug development processes, enhancing efficiency and accuracy. The use of artificial intelligence in drug development has shown promising results, allowing for faster identification of potential drug candidates and streamlining the overall research and development pipeline. With this investment, Persist AI aims to revolutionize drug discovery by harnessing the power of AI and robotics to bring novel therapeutics to market more effectively and efficiently.
Read more from bizjournals.com
